Related Experiment Video
Updated: Aug 8, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 19, 2013
Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells
1Department of Pathology, University of Maryland School of Medicine, Baltimore 21201, USA.
Abstract:
We investigated the effects of inositol hexaphosphate (InsP6) on growth inhibition and differentiation of human prostate cancer cells PC-3 in vitro. A significant dose- and time-dependent growth inhibition was observed as tested by the MTT-incorporation assay (P < 0.05 at 1 mM InsP6 after 24 h treatment, P < 0.01 at 0.1 mM after 3 days). DNA synthesis as determined by [3H]thymidine incorporation assay was also suppressed by InsP6 in a dose-dependent manner, occurring as early as 3 h after treatment and continuing up to 48 h (P < 0.01 at 1 mM InsP6). A 9- to 10-fold increase (P < 0.01) in expression of HLA class I molecule associated with tumor immunosurveillance and cell differentiation was induced by InsP6. The marker for prostatic cell differentiation, prostate acid phosphatase, was significantly (P < 0.05) increased after 48 h treatment at 0.5-5 mM InsP6. Since InsP6 strongly inhibits growth and induces differentiation in human prostate cancer cells in vitro, in vivo studies using a tumor xenograft model and a prostate carcinogenesis model are warranted to validate the efficacy of InsP6 in the treatment and prevention of prostate cancer.
Insights
Inositol hexaphosphate (InsP6) significantly inhibits human prostate cancer cell growth and DNA synthesis in vitro. InsP6 also promotes cancer cell differentiation, suggesting its potential for prostate cancer treatment and prevention.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Prostate cancer remains a significant health concern globally.
- Inositol hexaphosphate (InsP6) is a naturally occurring compound with potential anti-cancer properties.
- Understanding InsP6's effects on prostate cancer cells is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the effects of inositol hexaphosphate (InsP6) on the growth inhibition and differentiation of human prostate cancer cells (PC-3) in vitro.
- To assess the impact of InsP6 on DNA synthesis and the expression of key markers related to tumor immunosurveillance and cell differentiation.
Main Methods:
- Human prostate cancer cells (PC-3) were treated with varying concentrations of InsP6.
- Cell growth inhibition was measured using the MTT-incorporation assay.
- DNA synthesis was assessed via [3H]thymidine incorporation.
- Expression of HLA class I molecule and prostate acid phosphatase was analyzed.
Main Results:
- InsP6 demonstrated significant dose- and time-dependent inhibition of PC-3 cell growth (P < 0.05).
- InsP6 suppressed DNA synthesis in a dose-dependent manner, with effects observed as early as 3 hours post-treatment (P < 0.01).
- InsP6 significantly increased the expression of HLA class I molecule (9- to 10-fold, P < 0.01) and prostate acid phosphatase (P < 0.05), markers of tumor immunosurveillance and cell differentiation.
Conclusions:
- Inositol hexaphosphate (InsP6) exhibits potent in vitro efficacy in inhibiting prostate cancer cell growth and inducing differentiation.
- The observed effects on DNA synthesis and immune markers suggest a promising therapeutic potential for InsP6.
- Further in vivo studies are warranted to validate InsP6's efficacy in prostate cancer treatment and prevention models.
Related Concept Videos
01:42Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
02:34Inhibition of Cdk Activity